Immunomedics (IMMU) Misses Q4 EPS by 4c

Immunomedics (NASDAQ: IMMU) reported Q4 EPS of ($0.50), $0.04 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $295 thousand versus the consensus estimate of $530 thousand.

“We are pleased to have submitted our Biologics License Application (BLA) in late November – our top priority for 2019,” said Dr. Behzad Aghazadeh, executive chairman of Immunomedics. “While we are working closely with the FDA to facilitate their review of our BLA, we continued to execute against key initiatives across our commercial, clinical, and manufacturing operations. Our commercial team has been actively preparing for launch readiness, and, as we wait for an FDA decision, we are well positioned to commercialize sacituzumab govitecan in metastatic triple-negative breast cancer (mTNBC) on or before the June 2, 2020 PDUFA goal date. In addition, our main goals for 2020 include maximizing the global commercial potential of sacituzumab govitecan, while accelerating its development as a single agent and in combination with checkpoint inhibitors across a number of clinical settings to meet our commitment to help transform the lives of people with hard-to-treat cancers worldwide.”

For earnings history and earnings-related data on Immunomedics (IMMU) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c
• SanDisk unveils long-term growth strategy at 2026 Investor Day; Shares surge 12%